Vir Biotechnology, Inc. 8-K

What Happened
Vir Biotechnology, Inc. announced on Feb. 25, 2026 that it entered into an underwriting agreement to sell 17,647,059 shares of its common stock at $8.50 per share in a public offering. The offering is expected to close on Feb. 27, 2026, and the underwriters have a 30-day option to buy up to an additional 2,647,058 shares at the public offering price.

Key Details

• Shares offered: 17,647,059 common shares at $8.50 per share.
• Overallotment option: up to 2,647,058 additional shares (exercisable for 30 days), ~15% of the base offering.
• Expected net proceeds: approximately $141.1 million (about $162.3 million if the overallotment is fully exercised), after underwriting discounts, commissions and estimated offering expenses.
• Offering registered under an effective Form S-3ASR (filed Nov. 3, 2023); underwriting led by Goldman Sachs, Leerink Partners, Evercore and Barclays.

Why It Matters
This filing confirms Vir is raising capital through a significant equity offering, which will increase the company’s cash position by roughly $141 million (or up to $162 million if the option is exercised). For current shareholders, the sale will dilute ownership to the extent new shares are issued; for investors it signals the company’s need or desire for additional funding (e.g., for operations, R&D, or general corporate purposes). The offering terms, expected closing date, and underwriters are now public, giving investors concrete details to assess timing and potential dilution.